Literature DB >> 11164091

Comparative assessment of the anxiolytic-like activities of honokiol and derivatives.

H Kuribara1, E Kishi, M Kimura, S T Weintraub, Y Maruyama.   

Abstract

Honokiol has previously been shown to be an effective anxiolytic-like agent in mice when administered for 7 days at 0.2 mg/kg/day prior to evaluation in an elevated plus-maze, while 20 mg/kg is required for efficacy as a single oral dose. The aim of this study was to find analogs of honokiol that are more effective for acute administration. Among the eight analogs evaluated, one partially reduced derivative of honokiol [3'-(2-propenyl)-5-propyl-(1,1'-biphenyl)-2,4'-diol] exhibited significant anxiolytic-like activity at 0.04 mg/kg. Following oral administration of 1 mg/kg of this analog, anxiolytic-like activity was clearly evident at 1 h, peaked at 3 h, and remained significant for longer than 4 h after treatment. Combined administration of the derivative with diazepam led to enhanced anxiolytic-like efficacy. Moreover, as with diazepam, the anxiolytic-like effect of the analog was reduced by flumazenil. In contrast, bicuculline, a GABA(A) antagonist, had no effect on the activity of the derivative. Taken together, these results suggest that this analog of honokiol acts at the benzodiazepine recognition site of the GABA(A)-benzodiazepine receptor complex.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11164091     DOI: 10.1016/s0091-3057(00)00401-9

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  9 in total

1.  Honokiol promotes non-rapid eye movement sleep via the benzodiazepine site of the GABA(A) receptor in mice.

Authors:  Wei-Min Qu; Xiao-Fang Yue; Yu Sun; Kun Fan; Chang-Rui Chen; Yi-Ping Hou; Yoshihiro Urade; Zhi-Li Huang
Journal:  Br J Pharmacol       Date:  2012-10       Impact factor: 8.739

2.  The Pharmacokinetics and Tissue Distribution of Honokiol and its Metabolites in Rats.

Authors:  Wang Jun-Jun; Miao Xiao-Lei; Chen Jing-Ya; Chen Yong
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2016-10       Impact factor: 2.441

Review 3.  Honokiol, a multifunctional antiangiogenic and antitumor agent.

Authors:  Levi E Fried; Jack L Arbiser
Journal:  Antioxid Redox Signal       Date:  2009-05       Impact factor: 8.401

4.  Honokiol crosses BBB and BCSFB, and inhibits brain tumor growth in rat 9L intracerebral gliosarcoma model and human U251 xenograft glioma model.

Authors:  Xianhuo Wang; Xingmei Duan; Guangli Yang; Xiaoyan Zhang; Linyu Deng; Hao Zheng; Chongyang Deng; Jiaolin Wen; Ning Wang; Cheng Peng; Xia Zhao; Yuquan Wei; Lijuan Chen
Journal:  PLoS One       Date:  2011-04-29       Impact factor: 3.240

5.  In vitro inhibitory activities of magnolol against Candida spp.

Authors:  Peiru Zhou; Jingya Fu; Hong Hua; Xiaosong Liu
Journal:  Drug Des Devel Ther       Date:  2017-09-06       Impact factor: 4.162

Review 6.  Structure-Dependent Activity of Natural GABA(A) Receptor Modulators.

Authors:  Serhat Sezai Çiçek
Journal:  Molecules       Date:  2018-06-22       Impact factor: 4.411

Review 7.  Neuro-modulating effects of honokiol: a review.

Authors:  Anna Woodbury; Shan Ping Yu; Ling Wei; Paul García
Journal:  Front Neurol       Date:  2013-09-11       Impact factor: 4.003

8.  Support for Natural Small-Molecule Phenols as Anxiolytics.

Authors:  Xiaohong Wang; Yahong Chen; Qiang Wang; Lu Sun; Guiyun Li; Chanxi Zhang; Jianmei Huang; Lei Chen; Haifeng Zhai
Journal:  Molecules       Date:  2017-12-06       Impact factor: 4.411

9.  Synthesis of tetrahydrohonokiol derivates and their evaluation for cytotoxic activity against CCRF-CEM leukemia, U251 glioblastoma and HCT-116 colon cancer cells.

Authors:  Marketa Bernaskova; Nadine Kretschmer; Wolfgang Schuehly; Antje Huefner; Robert Weis; Rudolf Bauer
Journal:  Molecules       Date:  2014-01-20       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.